Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.
Agenovir Corp. won't use gene-editing to cut out defects or add in missing pieces in a patient's genome like most companies that are working with CRISPR/Cas9 constructs. Instead, it will use the technology to kill DNA that sits in latent viral reservoirs.
South San Francisco-based Agenovir believes that it has carved out a unique niche in the gene-editing space. The company's lead...
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
The Austrian firm is delisting from the NASDAQ and closing down.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Swiss giant has been talking to the US government about selling medicines directly to patients.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
